Search

Your search keyword '"Giacomelli, Andrea"' showing total 8 results
Start Over Author "Giacomelli, Andrea" Publication Year Range Last 50 years Journal clinical infectious diseases
8 results on '"Giacomelli, Andrea"'

3. Neutralizing Antibody Titers Induced by JYNNEOS Vaccine in Unrecognized Previous Mpox Virus–Exposed Individuals

Author

Moschese, Davide, primary, Bianchi, Micol, additional, Cossu, Maria Vittoria, additional, Salari, Federica, additional, Giacomelli, Andrea, additional, Rizzo, Alberto, additional, Lazzarin, Samuel, additional, Sabaini, Federico, additional, Nozza, Silvia, additional, Mileto, Davide, additional, Gori, Andrea, additional, Antinori, Spinello, additional, Gismondo, Maria Rita, additional, and Rizzardini, Giuliano, additional

Published
2023
Full Text
View/download PDF

4. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

Author

Waters, Laura, Assoumou, Lambert, González-Cordón, Ana, Rusconi, Stefano, Domingo, Pere, Gompels, Mark, de Wit, Stephane, Raffi, François, Stephan, Christoph, Masiá, Mar, Rockstroh, Jürgen, Katlama, Christine, Behrens, Georg M N, Moyle, Graeme, Johnson, Margaret, Fox, Julie, Stellbrink, Hans-Jürgen, Guaraldi, Giovanni, Florence, Eric, Esser, Stefan, Gatell, José M, Pozniak, Anton, Martínez, Esteban, Vandekerckhove, Linos, Caluwé, Els, Necsoi, Coca, Frankenhuijsen, Maartje Van, Allavena, Clotilde, Reliquet, Véronique, Boutoille, David, Cavellec, Morane, André-Garnier, Elisabeth, Rodallec, Audrey, Tourneau, Thierry Le, Connault, Jérôme, Molina, Jean-Michel, Ferret, Samuel, Previlon, Miresta, Yazdanpanah, Yazdan, Landman, Roland, Joly, Véronique, Pinto, Adriana, Caby, Fabienne, Ktorza, Nadine, Schneider, Luminita, Wolf, Timo, Schüttfort, Gundolf, Wasmuth, Jan-Christian, Schwarze-Zander, Carolynne, Boesecke, Christoph, Hoffmann, Christian, Sabranski, Michael, Esser, Stephan, Jablonka, Robert, Wiehler, Heidi, Stoll, Matthias, Ahrenstorf, Gerrit, Nardini, Giulia, Beghetto, Barbara, Montforte, Antonella D’Arminio, Bini, Teresa, Cogliandro, Viola, Di Pietro, Massimo, Fusco, Francesco Maria, Galli, Massimo, Giacomelli, Andrea, Meraviglia, Paola, Torres, Berta, Mateo, Gracia, Gutierrez, Mar, Portilla, Joaquin, Merino, Esperanza, Reus, Sergio, Boix, Vicente, Gutiérrez, Félix, Padilla, Sergio, Clotet, Bonaventura, Negredo, Eugenia, Bonjoch, Anna, Casado, José L, Bañón-Escandell, Sara, Saban, Jose, Duque, Africa, Podzamczer, Daniel, Saumoy, Maria, Acerete, Laura, Gonzalez-Garcia, Juan, Bernardino, José Ignacio, Arribas, José Ramón, Hontañón, Victor, Pagani, Nicole, Bracchi, Margherita, Vera, Jaime, Clarke, Amanda, Adams, Tanya, Richardson, Celia, Winston, Alan, Mora-Peris, Borja, Mullaney, Scott, Esteban, Nahum de, Milinkovic, Ana, Pett, Sarah, Tiraboschi, Juan Manuel, Youle, Mike, Orkin, Chloe, Rackstraw, Simon, Hand, James, Jennings, Louise, Nicholls, Jane, and Johnston, Sarah

Subjects
Microbiology (medical), Infectious Diseases, Medizin
Abstract

BackgroundIn the NEAT022 trial, virologically suppressed persons with human immunodeficiency virus (HIV) at high cardiovascular risk switching from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D) showed noninferior virological suppression and significant lipid and cardiovascular disease risk reductions on switching to dolutegravir relative to continuing protease inhibitors.MethodsIn post hoc analysis, major endpoints were 48-week and 96-week weight and body mass index (BMI) changes. Factors associated with weight/BMI changes within the first 48 weeks of DTG exposure, proportion of participants by category of percentage weight change, proportions of BMI categories over time, and impact on metabolic outcomes were also assessed.ResultsBetween May 2014 and November 2015, 204 (DTG-I) and 208 (DTG-D) participants were included. Weight significantly increased (mean, +0.810 kg DTG-I arm, and +0.979 kg DTG-D arm) in the first 48 weeks postswitch, but remained stable from 48 to 96 weeks in DTG-I arm. Switching from darunavir, White race, total to high-density lipoprotein cholesterol ratio ConclusionsSwitching from protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk led to modest weight gain limited to the first 48 weeks, which involved preferentially normal-weight or underweight persons and was not associated with negative metabolic outcomes.Clinical Trials RegistrationNCT02098837 and EudraCT 2013-003704-39.

Published
2022

5. Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine

Author

Capetti, Amedeo F, primary, Stangalini, Carlo A, additional, Borgonovo, Fabio, additional, Mileto, Davide, additional, Oreni, Letizia, additional, Dedivitiis, Gianfranco, additional, Lupo, Angelica, additional, Cossu, Maria V, additional, Bilardo, Lara, additional, Giacomelli, Andrea, additional, Galli, Massimo, additional, and Rizzardini, Giuliano, additional

Published
2021
Full Text
View/download PDF

7. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study

Author

Giacomelli, Andrea, primary, Pezzati, Laura, additional, Conti, Federico, additional, Bernacchia, Dario, additional, Siano, Matteo, additional, Oreni, Letizia, additional, Rusconi, Stefano, additional, Gervasoni, Cristina, additional, Ridolfo, Anna Lisa, additional, Rizzardini, Giuliano, additional, Antinori, Spinello, additional, and Galli, Massimo, additional

Published
2020
Full Text
View/download PDF

8. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

Author

Gatell, José M, Assoumou, Lambert, Moyle, Graeme, Waters, Laura, Johnson, Margaret, Domingo, Pere, Fox, Julie, Martinez, Esteban, Stellbrink, Hans-Jürgen, Guaraldi, Giovanni, Masia, Mar, Gompels, Mark, Wit, Stephane De, Florence, Eric, Esser, Stefan, Raffi, François, Stephan, Christoph, Rockstroh, Juergen, Giacomelli, Andrea, and Vera, Jaime

Subjects
THERAPEUTIC use of protease inhibitors, ANTIRETROVIRAL agents, CARDIOVASCULAR diseases risk factors, CHOLESTEROL, CONFIDENCE intervals, GENERIC drug substitution, HIV infections, LIPIDS, GENETIC mutation, RNA, VIRAL load, RANDOMIZED controlled trials, TREATMENT effectiveness
Abstract

Background Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)–based regimen to a dolutegravir (DTG)–based regimen may improve lipid profile. Methods European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)–infected adults aged ≥50 years or with a Framingham score ≥10% were eligible if HIV RNA was <50 copies/mL. Patients were randomized to switch from PI/r to DTG immediately (DTG-I) or to deferred switch at week 48 (DTG-D). Week 96 endpoints were proportion of patients with HIV RNA <50 copies/mL, percentage change of lipid fractions, and adverse events (AEs). Results Four hundred fifteen patients were randomized: 205 to DTG-I and 210 DTG-D. The primary objective of noninferiority at week 48 was met. At week 96, treatment success rate was 92.2% in the DTG-I arm and 87% in the DTG-D arm (difference, 5.2% [95% confidence interval, –.6% to 11%]). There were 5 virological failures in the DTG-I arm and 5 (1 while on PI/r and 4 after switching to DTG) in the DTG-D arm without selection of resistance mutations. There was no significant difference in terms of grade 3 or 4 AEs or treatment-modifying AEs. Total cholesterol and other lipid fractions (except high-density lipoprotein) significantly (P <.001) improved both after immediate and deferred switching to DTG overall and regardless of baseline PI/r strata. Conclusions Both immediate and deferred switching from a PI/r to a DTG regimen in virologically suppressed HIV-infected patients ≥50 years old or with a Framingham score ≥10% was highly efficacious and well tolerated, and improved the lipid profile. Clinical Trials Registration NCT02098837 and EudraCT: 2013-003704-39. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results